middle.news
Telix finds a bigger radiopharma platform in US$1.65 billion ITM deal
8:37am on Monday 21st of September, 2026 AEST
•
Healthcare
Read Story
Telix finds a bigger radiopharma platform in US$1.65 billion ITM deal
8:37am on Monday 21st of September, 2026 AEST
Key Points
US$1.65 billion upfront acquisition, including approximately US$1.25 billion in Telix shares
ITM shareholders expected to own 23.7% of Telix at completion
Up to US$700 million in milestone payments tied to ITM-11 approvals and sales
ITM generated US$273 million revenue in 2025 and supplies lutetium-177 globally
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Telix Pharmaceuticals (ASX:TLX)
OPEN ARTICLE